Antares Pharma October Catalyst Events: Makena Auto Injector and VIBEX QuickShot
Biotechnology

Antares Pharma October Catalyst Events: Makena Auto Injector and VIBEX QuickShot

Antares Pharma October Catalyst Events: Makena Auto Injector and VIBEX QuickShot. [Reuters] Antares Pharma, Inc. (NASDAQ:ATRS) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery .. Read More:

Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
Biotechnology

Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. Bellerophon Therapeutics Inc. (NASDAQ:BLPH), saw its shares jump in early trading after the company reported positive results in phase 2 clinical trials for INOpulse .. Read More:

joint meeting of The FDA to discuss Intellipharmaceutics' marketing application
Biotechnology

Joint meeting of The FDA to discuss Intellipharmaceutics’ marketing application for abuse-deterrent extended-release oxycodone; shares off 10% as investors digest briefing docs

Joint meeting of The FDA to discuss Intellipharmaceutics’ marketing application for abuse-deterrent extended-release oxycodone (oxycodone hydrochloride); shares off 10% as investors digest briefing docs. Joint meeting of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee .. Read More:

Bellerophon Therapeutics
Biotechnology

Bellerophon Therapeutics

Bellerophon Therapeutics: Research Report July 4, 2017. Bellerophon Therapeutics is the first company in our portfolio and the most important, because we believe Bellerophon to have massive upside potential. As of today (July 4, 2017), Bellerophon Therapeutics has two catalyst events. The first catalyst event .. Read More: